Injexate

Methotrexate, the active ingredient in Injexate, is an antimetabolite (folate antagonist) presented as a subcutaneous injection for systemic use. It works by inhibiting cell proliferation and suppressing immune responses, making it useful in the management of rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, and non‑Hodgkin lymphoma.

GNH USA supplies Injexate as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, pharmacies, and clinics worldwide through regulated procurement channels, ensuring quality and compliance with global standards and reliable delivery.

Methotrexate is used across autoimmune and oncologic disease pathways to reduce inflammation or inhibit malignant cell growth.

Rheumatoid arthritis: reduces joint inflammation and slows structural damage. Psoriasis: decreases skin cell proliferation, improving plaque severity. Acute lymphoblastic leukemia: interferes with DNA synthesis, leading to remission in many patients. Non‑Hodgkin lymphoma: suppresses tumor cell proliferation, contributing to disease control.

Methotrexate may cause a range of adverse reactions, varying from mild to potentially serious.

Common Side Effects: - Nausea and vomiting - Fatigue or malaise - Mucositis or mouth ulcers - Elevated liver enzymes - Cytopenias (low blood counts) - Alopecia (hair loss)

Serious or Rare Side Effects: - Severe liver fibrosis or cirrhosis - Pulmonary toxicity (interstitial pneumonitis) - Profound bone marrow suppression - Opportunistic infections - Renal toxicity - Severe cutaneous reactions (e.g., Stevens‑Johnson syndrome)

Methotrexate requires careful monitoring and specific safety measures.

Pregnancy: contraindicated (Category X) – avoid use in pregnant women. Renal function: assess before initiating; adjust dose in impairment. Liver function: monitor enzymes regularly; avoid in severe hepatic disease. Hematologic monitoring: perform regular CBC to detect cytopenias. Infection risk: screen for latent infections and avoid in active infections. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines that may alter its safety or efficacy.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Aminoglycoside antibiotics: potentiate renal toxicity. - Live vaccines: risk of severe infection. - Proton pump inhibitors: may raise serum methotrexate levels. - Trimethoprim‑sulfamethoxazole: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Sulfonylureas: may enhance hypoglycemia. - Cyclosporine: increased risk of hepatotoxicity. - Leucovorin rescue (folinic acid): may reduce methotrexate efficacy if given inadvertently.